Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascepa in hypertriglyceridemic patients with cardiovascular disease or high risk
NCT01492361Phase 3Completed
- Sponsor
- Amarin Corporation plc
- Start
- Nov 2011
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of omega-3 long-chain polyunsaturated fatty acids in cardiovascular disease (CVD) and hypertriglyceridemia (2 arms), sponsored by Amarin Corporation plc. Primary endpoint: Composite of CV Death, Nonfatal MI, Nonfatal Stroke, Coronary Revascularization, or Unstable Angina at 6 years. Started Nov 2011; status: completed.
02
Drugs
omega-3 long-chain polyunsaturated fatty acids
03
Conditions
cardiovascular disease (CVD)hypertriglyceridemia
Beyond the preview
Go deeper on NCT01492361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01492361.